MICROPRUNG : Intestinal Microbiota Analysis in Patients With or Without Hirschsprung's Associated EnteroColitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

118 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2018-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hirschsprung disease is a congenital abnormality due to the lack of migration of neural crest cells in myenteric and submucosal plexi of the bowel wall. The consequence is the absence of parasympathetic control of the distal bowel from the anal sphincter to various levels. The most common type of Hirschsprung disease alters the rectosigmoid (80%). The incidence is around 1/5000 live births. This anomaly requires a surgical ablation of the aganglionic segment.

Regardless of the surgical complications, patients with Hirschsprung disease are exposed to the risk of Hirschsprung Associated EnteroColitis (HAEC). This variable risk, 4-54%, is responsible to a major part of Hirschsprung disease morbimortality. Its onset is more frequent during the first two years of life and then decrease with age.

Its pathogenesis remains unclear but could be due to intestinal homeostasis breakdown that involves microbiota, intestinal barrier, immune system and enteric nervous system. This breakdown of the mutual benefit relation due to microbiota or bowel anomaly is known to be responsible of Crohn's disease onset. Some studies emphasize the role of microbiota in the pathogenesis of HAEC, but the techniques or the methodology with small numbers of patients limit any conclusion or clinical use.

The study hypothesizes microbiota is a major factor in HAEC onset and in their functional bowel problems. Considering HAEC is more frequent the first two years, it's thought that intestinal microbiota changes with time in those patients. This project is innovative because it will use high throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.

Multicentre transversal study.

This study has the potential to significantly modify clinical practice for Hirschsprung disease patients: a better care for HAEC and functional troubles thanks to a better understanding of their microbiota, targetted antibiotic treatment for HAEC, prophylactic treatment of patients at high risk of HAEC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Long Term Outcomes After Pull-through of Long Segment Hirschsprung Disease

NCT05461924

Constipation Incontinence Hirschsprung Disease, Long-Segment +1 more

UNKNOWN

Electrophysiological Activity of the Anorectum in Children Suspected of Hirschsprung Disease

NCT02342457

Hirschsprungs Disease

UNKNOWN NA

Endoscopic Mucosal Resection (EMR) for Diagnosis of Hirschsprung's Disease

NCT00671684

Chronic Constipation Hirschsprung's Disease

UNKNOWN PHASE1/PHASE2

Feasibility of Use of Indocyanine Green in Pediatric Colorectal Surgery

NCT04904081

Hirschsprung Disease Anorectal Malformations

RECRUITING PHASE3

Long-term Qualitative and Quantitative Outcomes of Children With Hirschsprung's Disease and Anorectal Malformations

NCT05450991

Hirschsprung Disease Anorectal Malformations

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary objective :

Characterize intestinal microbiota in patients with or without HAEC.

Secondary objectives :

* Look for a difference in microbiota composition between patients with or without HAEC ;
* Study the evolution with age of the microbiota in Hirschsprung disease patients ;
* Study predominant taxonomic classification elements in both groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hirschsprung Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fecal samples

High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.

Group Type OTHER

Fecal samples

Intervention Type OTHER

High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fecal samples

High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients from 0 to 16 years ;
* With rectosigmoid Hirschsprung's disease confirmed by rectal biopsies and at surgery;
* Already operated on, whatever the surgical technique was ;
* With a health care insurance;
* Clear information and signed consent form